CeriBell's Acceleration: From Seizure Detection to Brain Monitoring
Q2 2026 beats with 33% growth, record gross margin, and a FDA/CMS-fueled pipeline that points to a pivotal 2027.
CBLL · Earnings Call · 2026-08-10
A Quarter of Confirmation
CeriBell’s second-quarter 2026 earnings call was a study in momentum. The company delivered “revenue of $28.1 million growing 33% year over year” — Xingjuan Chao, Co Founder and Chief Executive Officer · 2026-08-10 — an acceleration from the 29% reported in Q1 — and raised full-year guidance to $114–117 million. More important than the top-line beat was the quality of the growth: record gross margin of 92% (89% excluding a $1.6 million tariff refund), 32 new accounts added to reach 712, and a steady string of FDA and CMS milestones that position 2027 as a “pivotal year.” The stock has responded, up 33% over the past 90 days, but the call suggests the story is just getting started. What stands out is how deliberately CeriBell is expanding its moat. The company is no longer just a seizure-detection point-of-care EEG. As CEO Jane Chao put it, “our longer term vision to establish EEG as a new vital sign is no longer theoretical” — Xingjuan Chao, Co Founder and Chief Executive Officer · 2026-08-10. That vision is now backed by a hardware platform with video, ECG, and continuous plug-in monitoring; two newly cleared algorithms (artifact rejection and epileptiform abnormality detection); and a Delirium launch that just received a CMS New Technology Add-on Payment (NTAP) worth up to $2,170 per qualified patient. These aren’t incremental tweaks — they’re the building blocks of a brain monitor that can sit beside standard vital signs.Built to Leverage
The financial engine behind this is a gross margin that would be the envy of most device companies. Even excluding the tariff refund, the 89% margin was “essentially back to where we were, even a little better, before all the tariff noise,” according to CFO Scott Blumberg (“that is a direct reflection of both the manufacturing move to Vietnam, but also some general cost reduction initiatives” — Scott Blumberg, Chief Financial Officer · 2026-08-10). This 87%+ gross margin on $28M quarterly revenue generates outsized gross profit — which CeriBell is deliberately reinvesting into its growth engine, keeping adjusted EBITDA loss roughly flat at ~$10M per quarter even as revenue compounds. The result is a classic “invest for the future” profile: total revenue up 29% YoY in the most recent filed quarter (though the call shows 33% for Q2) while operating losses widen as the company builds out sales infrastructure and R&D. The key to the leverage story is that CeriBell expects to add accounts faster without adding proportional headcount. Jane noted that the system level pipeline — the new strategic account management team targeting regional health systems — is “growing even faster than the already very health hospital level pipeline.” Scott reinforced this on the prior call, saying “We just had our largest quarter of net new adds since we have been a public company, and record usage per account.” — Scott Blumberg, Chief Financial Officer · 2026-05-11 That combination of top-down system contracts and same-store utilization expansion is what should drive the “repeatable growth engine” into 2027.2027: The Inflection Point
Every piece of this quarter’s news points to a 2027 that looks meaningfully different from 2026. The Neonate product is already generating purchase orders from both new and existing accounts; the delirium pilot is live at multiple sites with “positive feedback” and 40% of difficult-to-assess patients still monitorable; the new hardware platform — with full-montage coverage and multi-day wearability — is slated for a limited market release in the second half and a broader launch in 2027. When asked about revenue trajectory, Scott declined to guide but said “there are a lot of tailwinds that are all coalescing around at the same time” — Scott Blumberg, Chief Financial Officer · 2026-08-10 — a phrase that will likely be repeated by bulls over the coming year.The caution is familiar: CeriBell is a high-growth company burning cash. Net loss for Q2 2026 was $19.3M, and the company still hasn’t guided for cash flow breakeven. But with $129M in cash, a refinanced credit facility extended into 2031, and a gross margin that keeps climbing, the balance sheet is not the constraint. The real question is whether the commercial engine can keep up with the product cadence. Jane’s confidence is unwavering: “We are very proud of what we have accomplished this quarter and really excited about what is ahead of us.” — Xingjuan Chao, Co Founder and Chief Executive Officer · 2026-08-10 In a global context, CeriBell’s focus on AI-driven algorithms and hardware upgrades aligns with the broader care setting transformation across healthcare. But unlike many AI-medtech stories, CeriBell has hard regulatory wins and a clear reimbursement path. The epileptiform abnormality detection clearance — the first such FDA clearance for a software — underscores the company’s ability to convert clinical need into product. With less than 4% penetration in the core seizure market and greenfield indications like delirium and LVO looming, the runway is substantial. The next few quarters will test execution, but the direction is unmistakable.The NTAP, which becomes effective October 1, 2026, provides up to $2.17 thousand in incremental reimbursement per qualified patient. This is a meaningful milestone.